Business Context and Reporting Period
This Form 8-K filing by Inspire Medical Systems, Inc. (NYSE: INSP) reports a material corporate governance event. The report date is August 22, 2025, with the formal agreement signed on August 26, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and transition arrangements.
Material Changes
The primary material change is the departure of Richard J. Buchholz, the Company's Chief Financial Officer (CFO).
- Reason for Departure: Mr. Buchholz is stepping down to pursue other professional opportunities. The filing explicitly states the departure is not due to any dispute regarding operations, policies, accounting practices, or financial reporting.
- Transition Timeline: Mr. Buchholz will remain CFO until the earlier of December 31, 2025, or the date a permanent successor begins employment. He will serve in a financial advisory role through February 28, 2026.
- Succession: The Company has engaged an executive search firm to find a permanent replacement.
Compensation and Separation Terms
Under the Transition and Separation Agreement dated August 26, 2025, Mr. Buchholz will receive:
- Continuation of his current base salary and employee benefit plan eligibility through the effective date of his resignation.
- A cash payment equal to nine (9) months of his 2025 annual base salary (subject to taxes and withholdings).
- Up to nine (9) months of COBRA continuation coverage.
- Standard provisions for confidentiality, non-disparagement, and release of claims.
Outlook and Risks
The filing does not provide updated financial guidance or discuss new business risks. The primary operational risk noted is the interim period without a permanent CFO, which the Company is mitigating through Mr. Buchholz's continued advisory role and an active search for a successor.
Investor Verification Checklist
- Verify the exact date the permanent CFO successor is hired to determine the end of the transition period.
- Review the full text of the Transition and Separation Agreement (Exhibit 10.1) for specific clawback provisions or additional terms not summarized here.
- Monitor future filings for the appointment of the new CFO and any potential impact on the Company's financial reporting calendar.
- Confirm that no other undisclosed disputes exist regarding the Company's financial reporting, as explicitly stated in the filing.